Výsledky vyhledávání - "Kathryn F. Mileham"

Akademický článek

Prognostic Mutational Signatures of NSCLC Patients treated with chemotherapy, immunotherapy and chemoimmunotherapy

Autor: Margaret R. Smith, Yuezhu Wang, Ralph D’Agostino, Yin Liu, Jimmy Ruiz, Thomas Lycan, George Oliver, Lance D. Miller, Umit Topaloglu, Jireh Pinkney, Mohammed N. Abdulhaleem, Michael D. Chan, Michael Farris, Jing Su, Kathryn F. Mileham, Fei Xing

Publikováno v: npj Precision Oncology, Vol 7, Iss 1, Pp 1-8 (2023)

Abstract Different types of therapy are currently being used to treat non-small cell lung cancer (NSCLC) depending on the stage of tumor and the presence of potentially druggable mutations. However, few biomarkers are available to guide clinicians in

Externí odkaz: https://doaj.org/article/981166dcddae421ba6e1c51d9716f04c

Zobrazit plný text záznamu

Akademický článek

Lorlatinib Tolerability and Association With Clinical Outcomes in Patients With Advanced ALK- or ROS1-Rearranged NSCLC: A Brief Report

Autor: Rohit Thummalapalli, MD, Noura J. Choudhury, MD, Fiona Ehrich, MS, Tyler Beardslee, PharmD, Danielle Brazel, MD, Shannon S. Zhang, MD, Shelby Merchant, PharmD, Monica F. Chen, MD, Glenn Heller, PhD, Suresh S. Ramalingam, MD, Sai-Hong Ignatius Ou, MD, PhD, Kathryn F. Mileham, MD, Gregory J. Riely, MD, PhD

Publikováno v: JTO Clinical and Research Reports, Vol 4, Iss 8, Pp 100546- (2023)

Introduction: Treatment with lorlatinib for patients with advanced ALK- and ROS1-rearranged NSCLC (ALK+ and ROS1+ NSCLC) is associated with a unique set of adverse events (AEs) often requiring dose reduction. However, the impact of dose reductions on

Externí odkaz: https://doaj.org/article/4a17b716e5554aaa9e42589db4af6e82

Zobrazit plný text záznamu

Akademický článek

Defining comprehensive biomarker‐related testing and treatment practices for advanced non‐small‐cell lung cancer: Results of a survey of U.S. oncologists

Autor: Kathryn F. Mileham, Caroline Schenkel, Suanna S. Bruinooge, Janet Freeman‐Daily, Upal Basu Roy, Amy Moore, Robert A. Smith, Elizabeth Garrett‐Mayer, Lauren Rosenthal, Edward B. Garon, Bruce E. Johnson, Raymond U. Osarogiagbon, Shadia Jalal, Shamsuddin Virani, Mary Weber Redman, Gerard A. Silvestri

Publikováno v: Cancer Medicine, Vol 11, Iss 2, Pp 530-538 (2022)

Abstract Background An ASCO taskforce comprised of representatives of oncology clinicians, the American Cancer Society National Lung Cancer Roundtable (NLCRT), LUNGevity, the GO2 Foundation for Lung Cancer, and the ROS1ders sought to: characterize U.

Externí odkaz: https://doaj.org/article/77e04cdb969842218b3ff0a67980c00e

Zobrazit plný text záznamu

Plný text ve formátu HTML

Akademický článek

Trial Reporting in Immuno-Oncology (TRIO): An American Society of Clinical Oncology-Society for Immunotherapy of Cancer Statement

Autor: Apostolia M. Tsimberidou, Laura A. Levit, Richard L. Schilsky, Steven D. Averbuch, Daniel Chen, John M. Kirkwood, Lisa M. McShane, Elad Sharon, Kathryn F. Mileham, Michael A. Postow

Publikováno v: Journal for ImmunoTherapy of Cancer, Vol 6, Iss 1, Pp 1-10 (2018)

Abstract Purpose To develop recommendations for clinical trial reporting that address the unique efficacy, toxicity, and combination and sequencing aspects of immuno-oncology (IO) treatments. Methods ASCO and the Society for Immunotherapy of Cancer (

Externí odkaz: https://doaj.org/article/00fcda6541714e90a7d4b3def16e9979

Zobrazit plný text záznamu

Association of Antifolate Response Signature Status and Clinical Activity of Pemetrexed-Platinum Chemotherapy in Non-Small Cell Lung Cancer - The Piedmont Study

Autor: Joel R. Eisner, Gregory M. Mayhew, James M. Davison, Kirk D. Beebe, Yoichiro Shibata, Yuelong Guo, Carol Farhangfar, Farhang Farhangfar, Joshua M. Uronis, Jeffrey M. Conroy, Michael V. Milburn, David Neil. Hayes, Kathryn F. Mileham

Publikováno v: Clinical Cancer Research.

Purpose: The Piedmont study is a prospectively designed retrospective evaluation of a new 48-gene antifolate response signature (AF-PRS) in patients with locally advanced/metastatic NS-NSCLC treated with pemetrexed-containing platinum doublet chemoth

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::43c4953b0bb03f5b73d0ac32e56d115c
https://doi.org/10.1158/1078-0432.ccr-22-2558

Zobrazit plný text záznamu

Defining comprehensive biomarker‐related testing and treatment practices for advanced non‐small‐cell lung cancer: Results of a survey of U.S. oncologists

Publikováno v: Cancer Medicine, Vol 11, Iss 2, Pp 530-538 (2022)
Cancer Medicine

Background An ASCO taskforce comprised of representatives of oncology clinicians, the American Cancer Society National Lung Cancer Roundtable (NLCRT), LUNGevity, the GO2 Foundation for Lung Cancer, and the ROS1ders sought to: characterize U.S. oncolo

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a743d8eed47c3c35fb21a4af673b0c7f
https://doi.org/10.1002/cam4.4459

Zobrazit plný text záznamu

Impact of a Clinical Genomics Program on Trial Accrual for Targeted Treatments: Practical Approach Overcoming Barriers to Accrual for Underserved Patients

Autor: Carol J. Farhangfar, Gregory T. Scarola, Victoria A. Morris, Farhang Farhangfar, Kathryn Dumas, James Symanowski, Jimmy J. Hwang, Kathryn F. Mileham, Daniel R. Carrizosa, R. Wendel Naumann, Chad Livasy, Edward S. Kim, Derek Raghavan

Publikováno v: JCO clinical cancer informatics. 6

PURPOSE Clinical trials of novel and targeted agents increasingly require biomarkers for eligibility. Precision oncology continues to evolve, but challenges hamper broad use of molecular profiling (MP) that could increase the number of patients benef

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::174aebd5509724536d208dbd3c06e268
https://pubmed.ncbi.nlm.nih.gov/35839431

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání